Poly(amido)amine (PAMAM) dendrimer–cisplatin complexes for chemotherapy of cisplatin-resistant ovarian cancer cells
Source abstract
Abstract
Dendrimer–cisplatin complexes were prepared using PAMAM dendrimers with terminal –NH2 and –COOH groups as well as biotin-conjugated dendrimers. Preformulation parameters of dendrimer–cisplatin complexes were studied using differential scanning calorimetry (DSC) and inductively coupled plasma-mass spectrometry (ICP-MS). Cytotoxicity and mechanism of cytotoxicity of dendrimer-cisplatin complexes was investigated in OVCAR-3, SKOV, A2780 and cisplatin-resistant CP70 human ovarian cancer cell lines. The loading of cisplatin in dendrimers was ~11 % (w/w). PAMAM G4 dendrimers with amine surface groups (biotinylated and native) have shown 2.5- to 3.0-fold reduction in IC50 values in ovarian cancer cells when compared with carboxylate surface dendrimers (p < 0.05). A correlation was observed among cytotoxicity of the complexes, cellular uptake, and platinum–DNA adduct formation. Treatment with dendrimer–cisplatin complexes resulted in a 7.0-fold increase (p < 0.05) in expression of apoptotic genes (Bcl2, Bax, p53) and 13.2- to 27.1-fold increase (p < 0.05) in the activity of caspases 3, 8, and 9 in vitro. Results suggest that PAMAM dendrimers can be used as potential carrier for cisplatin chemotherapy of ovarian cancer.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · Metal complexes synthesis and properties · Ferrocene Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. American Cancer Society (2011) Ovarian cancer-detailed guide-ovarian cancer key statistics. www.cancer.org
2. Andrews PA (1994) Mechanisms of acquired resistance to cisplatin. Cancer Treat Res 73:217–24810.1007/978-1-4615-2632-2_11 ↗
3. Boulikas T (2009) Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18(8):1197–1218. doi: 10.1517/1354378090311416810.1517/13543780903114168 ↗
4. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14(1):22–34. doi: 10.1016/j.drup.2010.12.00210.1016/j.drup.2010.12.002 ↗
5. Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G, Canevari S (1997) Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med 38(9):1378–1381
6. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278(5345):1966–196810.1126/science.278.5345.1966 ↗
7. Echarri Gonzalez MJ, Green R, Muggia FM (2011) Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology (Williston Park) 25(2):156–165
8. El-Sayed M, Rhodes CA, Ginski M, Ghandehari H (2003) Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm 265(1–2):151–15710.1016/S0378-5173(03)00391-0 ↗
9. Fischer U, Janicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10(1):76–100. doi: 10.1038/sj.cdd.440116010.1038/sj.cdd.4401160 ↗
10. Grandgirard D, Studer E, Monney L, Belser T, Fellay I, Borner C, Michel MR (1998) Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J 17(5):1268–1278. doi: 10.1093/emboj/17.5.126810.1093/emboj/17.5.1268 ↗
11. Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K (2007) Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm 67(1):1–8. doi: 10.1016/j.ejpb.2006.12.01710.1016/j.ejpb.2006.12.017 ↗
12. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193–204. doi: 10.1038/nrc234210.1038/nrc2342 ↗
13. Ho YP, Au-Yeung SC, To KK (2003) Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 23(5):633–655. doi: 10.1002/med.1003810.1002/med.10038 ↗
14. Jevprasesphant R, Penny J, Attwood D, D’Emanuele A (2004) Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J Control Release 97(2):259–267. doi: 10.1016/j.jconrel.2004.03.02210.1016/j.jconrel.2004.03.022 ↗
15. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573–584. doi: 10.1038/nrc216710.1038/nrc2167 ↗
16. Kim YM, Kim TH, Seol DW, Talanian RV, Billiar TR (1998) Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J Biol Chem 273(47):31437–3144110.1074/jbc.273.47.31437 ↗
17. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ (2011) Evaluation of anionic half generation 3.5–6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem 105(9):1115–1122. doi: 10.1016/j.jinorgbio.2011.05.01710.1016/j.jinorgbio.2011.05.017 ↗
18. Kojima C, Kono K, Maruyama K, Takagishi T (2000) Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem 11(6):910–91710.1021/bc0000583 ↗
19. Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 107(42):17939–17944. doi: 10.1073/pnas.101136810710.1073/pnas.1011368107 ↗
20. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4):491–50110.1016/S0092-8674(00)81590-1 ↗
21. Malik N, Evagorou EG, Duncan R (1999) Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10(8):767–77610.1097/00001813-199909000-00010 ↗
22. Mamede M, Saga T, Kobayashi H, Ishimori T, Higashi T, Sato N, Brechbiel MW, Konishi J (2003) Radiolabeling of avidin with very high specific activity for internal radiation therapy of intraperitoneally disseminated tumors. Clin Cancer Res 9(10 Pt 1):3756–3762
23. Marques-Gallego P, Kalayda GV, Jaehde U, Dulk H, Brouwer J, Reedijk J (2009) Cellular accumulation and DNA platination of two new platinum(II) anticancer compounds based on anthracene derivatives as carrier ligands. J Inorg Biochem 103(5):791–796. doi: 10.1016/j.jinorgbio.2009.02.00510.1016/j.jinorgbio.2009.02.005 ↗
24. Nishiyama N, Kataoka K (2001) Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. J Control Release 74(1–3):83–9410.1016/S0168-3659(01)00314-5 ↗
25. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K (2001) Cisplatin-loaded polymer–metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res 18(7):1035–104110.1023/A:1010908916184 ↗
26. Park JH, von Maltzahn G, Xu MJ, Fogal V, Kotamraju VR, Ruoslahti E, Bhatia SN, Sailor MJ (2010) Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci USA 107(3):981–986. doi: 10.1073/pnas.090956510710.1073/pnas.0909565107 ↗
27. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34(10):1535–154210.1016/S0959-8049(98)00227-5 ↗
28. Piccart MJ, Lamb H, Vermorken JB (2001) Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 12(9):1195–120310.1023/A:1012259625746 ↗
29. Prasad PD, Wang H, Kekuda R, Fujita T, Fei YJ, Devoe LD, Leibach FH, Ganapathy V (1998) Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantothenate, biotin, and lipoate. J Biol Chem 273(13):7501–750610.1074/jbc.273.13.7501 ↗
30. Prasad PD, Wang H, Huang W, Fei YJ, Leibach FH, Devoe LD, Ganapathy V (1999) Molecular and functional characterization of the intestinal Na+-dependent multivitamin transporter. Arch Biochem Biophys 366(1):95–106. doi: 10.1006/abbi.1999.121310.1006/abbi.1999.1213 ↗
31. Reedijk J, Lohman PH (1985) Cisplatin: synthesis, antitumour activity and mechanism of action. Pharm Weekbl Sci 7(5):173–18010.1007/BF02307573 ↗
32. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D (2004) Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98(10):1625–1633. doi: 10.1016/j.jinorgbio.2004.07.00910.1016/j.jinorgbio.2004.07.009 ↗
33. Russell-Jones G, McTavish K, McEwan J (2011) Preliminary studies on the selective accumulation of vitamin-targeted polymers within tumors. J Drug Target 19(2):133–139. doi: 10.3109/1061186100373402710.3109/10611861003734027 ↗
34. Seib FP, Jones AT, Duncan R (2007) Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM dendrimers in B16f10 melanoma cells. J Control Release 117(3):291–300. doi: 10.1016/j.jconrel.2006.10.02010.1016/j.jconrel.2006.10.020 ↗
35. Shahzad MM, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6):148–152. doi: 10.1016/j.drup.2009.09.00110.1016/j.drup.2009.09.001 ↗
36. Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A, Horikiri Y, Suzuki T, Yoshino H, Ike O (2002) Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm 54(1):1–710.1016/S0939-6411(02)00037-1 ↗
37. Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81(5):801–80910.1016/0092-8674(95)90541-3 ↗
38. Wilbur DS, Pathare PM, Hamlin DK, Buhler KR, Vessella RL (1998) Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug Chem 9(6):813–825. doi: 10.1021/bc980055e10.1021/bc980055e ↗
39. Yan X, Gemeinhart RA (2005) Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J Control Release 106(1–2):198–208. doi: 10.1016/j.jconrel.2005.05.00510.1016/j.jconrel.2005.05.005 ↗
40. Yellepeddi VK, Kumar A, Palakurthi S (2009a) Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. Anticancer Res 29(8):2933–2943
41. Yellepeddi VK, Kumar A, Palakurthi S (2009b) Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications. Expert Opin Drug Deliv 6(8):835–850. doi: 10.1517/1742524090306125110.1517/17425240903061251 ↗
42. Yellepeddi VK, Kumar A, Maher DM, Chauhan SC, Vangara KK, Palakurthi S (2011) Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 31(3):897–906
43. Zhang XM, Lin H, Chen C, Chen BD (1999) Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J 340(Pt 1):127–13310.1042/0264-6021:3400127 ↗
44. Zhu J, Xiong L, Yu B, Wu J (2005) Apoptosis induced by a new member of saponin family is mediated through caspase-8-dependent cleavage of Bcl-2. Mol Pharmacol 68(6):1831–1838. doi: 10.1124/mol.105.01582610.1124/mol.105.015826 ↗
45. Zhu J, Yang Y, Wu J (2007) Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cell Res 17(5):441–448. doi: 10.1038/cr.2007.3610.1038/cr.2007.36 ↗